Replies to post #221286 on Biotech Values

[DewDiligence]

ABBV/ENTA/GILD—Mavyret’s US new-patient share=53.4%—the highest-ever weekly figure—in the week ending 10/5/18, as reported by IMS. GILD’s US new-patient share was 45.6%, and MRK’s was 1.0%.

Mavyret’s US total-script share was 47.2% in the week ending 10/5/18, slightly below the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 51.6%, and MRK’s was 1.1%.